Dr. Kevin Dahl comes to Spheryx with a wealth of experience in analytical instrumentation to be our new Director of Technical Operations and Sales.

New York, NY – Spheryx Inc. is pleased to announce that Kevin Dahl, PhD, will be joining Spheryx as Director of Technical Operations and Sales. Kevin joins Spheryx with deep experience in analytical instrumentation. Kevin holds a PhD in Chemistry, a Post-Doc at the US Naval Research Laboratory and spent 10 years with Malvern Panalytical, one of the preeminent analytical instruments companies internationally. At Malvern he was an expert on microspectroscopy and light scattering with an emphasis on bioscience applications. After Malvern, Kevin spent 6 years building the Particle Characterization Core at KBI Biopharma, a premiere analytical services company based in Colorado. Two years ago he founded Particlese, a consultancy specializing in pharmaceutical particulates.

Spheryx CEO Laura Philips shared, “We are thrilled to have Kevin join the Spheryx team. His background extends our expertise in particle characterization and its applications. He has already hit the ground running.” Dr. Dahl adds, “Spheryx is a perfect fit for me. I am excited to be joining the company at a time where Spheryx’s Total Holographic Characterization is becoming an established technology in applications in biologic pharmaceuticals and semiconductors, and I look forward to the growth in these as well as other new markets.”

About Spheryx, Inc.

Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic Characterization® of colloidal materials. Spheryx’s proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, offering unprecedented insights into these materials’ characteristics. Applications include R&D, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs.

Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or result to differ materially.